ABIVAX Publishes 2016 Shareholder Newsletter
HIV drug candidate ABX464 and the history of HIV/AIDS
Paris, May 9th, 2016 - ABIVAX (Euronext Paris: FR0012333284 - ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it has published its first shareholder newsletter, highlighting the history of HIV/AIDS and ABIVAX's HIV drug candidate, ABX464, which is in mid-stage clinical testing.
Currently available therapies are able to control the disease in most patients with HIV/AIDS, but there is still a large medical need for treatments that offer a functional cure or real cure. ABX464 may have the potential to provide a functional cure for HIV/AIDS because it does not appear to induce resistance and has a long-lasting effect. Formulated as a once-daily oral pill, ABX464 is easy to use. In testing to-date, its tolerability profile has been consistent with that of marketed HIV drugs.
Further information on ABIVAX, the history and current state of HIV/AIDS, and the innovative drug candidate ABX464 is available in the ABIVAX April 2016 newsletter, available by clicking here.
ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and therapeutic vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com.
Follow us on Twitter @ABIVAX_
Paris, May 9th, 2016 - ABIVAX (Euronext Paris: FR0012333284 - ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it has published its first shareholder newsletter, highlighting the history of HIV/AIDS and ABIVAX's HIV drug candidate, ABX464, which is in mid-stage clinical testing.
Currently available therapies are able to control the disease in most patients with HIV/AIDS, but there is still a large medical need for treatments that offer a functional cure or real cure. ABX464 may have the potential to provide a functional cure for HIV/AIDS because it does not appear to induce resistance and has a long-lasting effect. Formulated as a once-daily oral pill, ABX464 is easy to use. In testing to-date, its tolerability profile has been consistent with that of marketed HIV drugs.
Further information on ABIVAX, the history and current state of HIV/AIDS, and the innovative drug candidate ABX464 is available in the ABIVAX April 2016 newsletter, available by clicking here.
ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and therapeutic vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com.
Follow us on Twitter @ABIVAX_